Emerald Bioscience (OTCMKTS:EMBI) Hits New 1-Year High at $13.45

Emerald Bioscience Inc. (OTCMKTS:EMBIGet Free Report) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $13.45 and last traded at $10.00, with a volume of 127724 shares traded. The stock had previously closed at $13.33.

Emerald Bioscience Trading Down 25.0 %

The business has a fifty day moving average of $6.09 and a 200-day moving average of $3.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.59 and a current ratio of 3.59. The company has a market capitalization of $2.68 billion, a P/E ratio of -166.56 and a beta of 0.43.

Emerald Bioscience Company Profile

(Get Free Report)

Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.

Featured Stories

Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.